Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.

Study Summary

The purpose of this study is to generate additional safety and effectiveness data in Indian Diabetic macular edema (DME) patients that more closely resemble the real-world population intended to be treated with Brolucizumab. This study is being conducted as part of the post-marketing regulatory commitment to the Indian Health authority.

Conditions

Diabetic Macular Edema

Interventions / Drugs

brolucizumab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment63 participants

Primary Completion—

Lead SponsorNovartis Pharmaceuticals

Data Retrieved2026-04-11 02:55:49.151761+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.